Back to top
more

ImmunoGen, Inc. (IMGN)

(Delayed Data from NSDQ)

$2.88 USD

2.88
5,883,771

+0.38 (15.20%)

Updated May 3, 2019 04:00 PM ET

After-Market: $2.93 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Corvus' (CRVS) Lymphoma Drug Gets Orphan Status, Stock Up

by Zacks Equity Research

Corvus' (CRVS) lead candidate, soquelitinib, gets orphan drug designation in the United States. The company???s shares rise 10.75% on the news.

Humacyte (HUMA) Up on HAV BLA Priority Tag for Vascular Trauma

by Zacks Equity Research

Humacyte (HUMA) gains 16% as the FDA accepts its BLA for the HAV bioengineered tissue to treat vascular trauma under Priority Review. A final decision is expected in August 2024.

Ionis' (IONS) Eplontersen Gets Fast Track Tag for New Indication

by Zacks Equity Research

The FDA bestows a Fast Track designation to Ionis (IONS) and partner AstraZeneca's (AZN) eplontersen for treating adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).

Foghorn (FHTX) Jumps 55% as Lilly Takes Up FHD-909 Development

by Zacks Equity Research

Foghorn (FHTX) gains 55% as its strategic collaboration partner, Lilly, selects the pre-clinical candidate, FHD-909, for clinical development.

Is ImmunoGen (IMGN) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how ImmunoGen (IMGN) and Achilles Therapeutics PLC Sponsored ADR (ACHL) have performed compared to their sector so far this year.

ImmunoGen (IMGN) Soars 5.7%: Is Further Upside Left in the Stock?

by Zacks Equity Research

ImmunoGen (IMGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Bristol Myers' (BMY) Opdivo Label Expansion Filings Get Accepted

by Zacks Equity Research

Bristol Myers (BMY) announces the acceptance of its regulatory filings for the perioperative Opdivo regimen to treat a lung cancer indication in the United States and EU.

JAZZ Boosts Oncology Pipeline With KRAS Inhibitor Program

by Zacks Equity Research

JAZZ inks a deal to acquire global rights to Redx Pharma's KRAS inhibitor program to strengthen its early-stage oncology pipeline.

REGENXBIO's (RGNX) Hunter Syndrome Study Meets Goal, Stock Up

by Zacks Equity Research

REGENXBIO (RGNX) gains 12% on positive top-line results from the phase I/II/III study of its investigational one-time gene therapy candidate, RGX-121, to treat pediatric patients with Hunter syndrome.

Deciphera (DCPH) Q4 Loss Narrower Than Expected, Revenues Beat

by Zacks Equity Research

Deciphera (DCPH) reports better-than-expected fourth-quarter 2023 results, wherein both earnings and revenues beat their respective estimates, driven by increased Qinlock sales.

Should First Trust Mid Cap Core AlphaDEX ETF (FNX) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for FNX

Is First Trust Mid Cap Core AlphaDEX ETF (FNX) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FNX

Gilead (GILD) Down as NSCLC Study Fails to Meet Primary Goal

by Zacks Equity Research

Gilead Sciences' (GILD) phase III study evaluating Trodelvy (sacituzumab govitecan) in previously treated metastatic NSCLC fails to meet its primary endpoint. Shares decline on the same.

Should First Trust Mid Cap Growth AlphaDEX ETF (FNY) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for FNY

Should JPMorgan BetaBuilders U.S. Small Cap Equity ETF (BBSC) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for BBSC

How ImmunoGen (IMGN) Stock Stands Out in a Strong Industry

by Zacks Equity Research

ImmunoGen (IMGN) has seen solid earnings estimate revision activity over the past two month, and belongs to a strong industry as well.

All You Need to Know About ImmunoGen (IMGN) Rating Upgrade to Strong Buy

by Zacks Equity Research

ImmunoGen (IMGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Best Momentum Stocks to Buy for January 4th

by Zacks Equity Research

IMGN and GTLB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 4, 2024.

New Strong Buy Stocks for January 4th

by Zacks Equity Research

IMGN, GTLB, FNWD, BL and TMHC have been added to the Zacks Rank #1 (Strong Buy) List on January 4, 2024.

Is Arvinas (ARVN) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Arvinas, Inc. (ARVN) and ImmunoGen (IMGN) have performed compared to their sector so far this year.

Andrew Rocco headshot

5 Reasons to be Bullish into 2024

by Andrew Rocco

Stock Strategist Andrew Rocco unveils 5 bullish undercurrents that will push stocks even higher into the new year.

Abhinab Dasgupta headshot

Beat the Market the Zacks Way: Shopify, Lululemon, Telos in Focus

by Abhinab Dasgupta

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Why Is Esperion Therapeutics (ESPR) Up 51.4% Since Last Earnings Report?

by Zacks Equity Research

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AbbVie (ABBV) to Acquire Cerevel Therapeutics (CERE) for $8.7B

by Zacks Equity Research

AbbVie (ABBV) offers to buy Cerevel Therapeutics (CERE) for $8.7 billion. The acquisition will strengthen AbbVie's neuroscience pipeline.

ImmunoGen (IMGN) Gets FDA Priority Review for Elahere sBLA

by Zacks Equity Research

The FDA grants priority review to ImmunoGen's (IMGN) sBLA to convert the accelerated approval for Elahere to full approval for treating platinum-resistant ovarian cancer. A decision is due on Apr 5, 2024.